UK-Based Firm Taps Microsoft's Azure Cloud to Support Predictive Drug Discovery | GenomeWeb

UK-based drug discovery services firm Molplex is using Microsoft’s cloud infrastructure to build its computational compound screening business.

Molplex collaborated with Microsoft Research Connections to build its Clouds Against Disease service, which is based on Microsoft's Azure cloud platform and runs proprietary virtual screening algorithms.

David Leahy, Molplex’s CEO, explained that the company began developing the computational candidate screening technology about six or seven years ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.